STOCK TITAN
  1. Home
  2. News
  3. ALKS

Alkermes plc - ALKS STOCK NEWS

Welcome to our dedicated news page for Alkermes plc (Ticker: ALKS), a resource for investors and traders seeking the latest updates and insights on Alkermes plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Alkermes plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Alkermes plc's position in the market.

News
Alkermes' Culture of Employee Engagement and Wellness
Rhea-AI Summary
Alkermes (ALKS) prioritizes employee engagement and mental health in the workplace, offering a comprehensive range of benefits and resources. The company's commitment to employee well-being includes frequent leadership communications, in-person social events, and enhanced employee resources. Alkermes also focuses on learning and development through programs like Leading@Alkermes, Leadership in Action, and LinkedIn Learning. The company's dedication to recognizing and appreciating employees is evident through the RISE recognition program. Alkermes also places emphasis on employee benefits and wellness, offering initiatives for physical, emotional, and financial well-being. The company's efforts to prioritize mental health in the workplace have been recognized with the Platinum Level Bell Seal from Mental Health America.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
News
Alkermes plc Announces Agreement to Sell Athlone, Ireland Facility to Novo Nordisk
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk for a one-time cash payment of $92.5 million. The transaction is expected to drive operational efficiencies and enhance profitability over the long term, and Alkermes will retain all royalty revenues associated with products currently manufactured at the facility. The company will continue to manufacture its proprietary commercial products at its Wilmington, Ohio manufacturing facility.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.71%
Tags
none
-
News
Patient Advocacy and Community Engagement at Alkermes
Rhea-AI Summary
Alkermes (ALKS) Develops and Manufactures Proprietary Medicines for Alcohol Dependence, Opioid Dependence, Schizophrenia, and Bipolar I Disorder
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
none
News
Pharmaceuticals in the Environment
Rhea-AI Summary
Alkermes (ALKS) focuses on environmental responsibility and biodiversity conservation in its operations. The company implements strict protocols to mitigate environmental impacts, partners with experts to understand eco-toxicology, and enhances biodiversity at its facilities. Alkermes aims to become more environmentally sustainable through science- and data-driven strategies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.02%
Tags
none
-
News
Alkermes to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) will participate in fireside chat presentations at two upcoming investor conferences, including the Piper Sandler 35th Annual Healthcare Conference and the 6th Annual Evercore ISI HealthCONx Conference. The live webcasts can be accessed on www.alkermes.com and will be archived for 14 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.61%
Tags
conferences
-
News
Environmental Protection & Sustainability at Alkermes
Rhea-AI Summary
Alkermes plc (ALKS) focuses on environmental protection and sustainability, striving to minimize environmental impacts, comply with regulations, and promote sustainability. The company has identified key environmental focus areas, including energy use, waste optimization, pharmaceuticals in the environment, water conservation, sustainability in the supply network, and biodiversity. Alkermes has established a sustainability steering team and is working with an independent consultant to enhance its environmental sustainability strategy and disclosures. The company has implemented various initiatives to reduce energy usage and GHG emissions, including the installation of EV charging stations and the use of renewable electricity generation. Despite an increase in absolute source water usage, Alkermes has decreased overall water consumption compared to the baseline year of 2015.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
none
News
Alkermes' Waste Optimization Highlights
Rhea-AI Summary
Alkermes (ALKS) Waste Optimization Highlights in 2022: Alkermes published its September 2023 Corporate Responsibility Report, detailing comprehensive waste management plans at all its facilities. The report emphasizes the company's commitment to reducing waste generation and embracing circularity, reusing, repairing, refurbishing, and recycling materials. Key highlights include 98% of total waste generated in 2022 being recycled, processed in waste-to-energy facilities, or incinerated. The Wilmington facility recycled 30 tonnes of heptane and 1,528 tonnes of ethanol, representing 97% of hazardous waste generated. No waste from the Athlone facility was sent to landfill, and 100% of non-hazardous waste and 93% of hazardous waste were either recycled or processed in waste-to-energy facilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
-
News
Alkermes Completes Separation of Oncology Business
Rhea-AI Summary
Alkermes plc (Nasdaq: ALKS) Completes Oncology Business Separation, Emerges as Profitable Neuroscience Company, and Updates Financial Expectations for 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
none
-
News
Our Commitment to Caregivers
Rhea-AI Summary
Alkermes (ALKS) Recognizes National Caregivers Month 2023, Highlights Support for Caregiving Employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.88%
Tags
none
News
Product Stewardship and Environmental Impact at Alkermes
Rhea-AI Summary
Alkermes (ALK) Corporate Responsibility Report Highlights Commitment to Product Stewardship and Environmental Impact
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
none
Stock ALKS logo
Alkermes plc

Nasdaq:ALKS

ALKS Rankings

#1311 Ranked by Market Cap
#1668 Ranked by Stock Gains
N/A Ranked by Dividends

ALKS Stock Data

4.02B
158.79M
1.25%
108.01%
8.58%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Ireland
Dublin

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.